PerkinElmer acquires BioLegend for $5.25B

By The Science Advisory Board staff writers

September 20, 2021 -- PerkinElmer announced it has completed its $5.25 billion acquisition of life science antibody and reagent company BioLegend, a deal first announced in July.

The acquisition expands PerkinElmer's life science portfolio into cytometry, proteogenomics, multiplex assays, recombinant proteins, magnetic cell separation, and bioprocessing.

PerkinElmer releases new KRAS investigation kits
PerkinElmer has released four new test kits designed to help researchers better understand KRAS protein structures and mutations. The kits will enable...
PerkinElmer posts growth in Q2
PerkinElmer posted revenue and operating income increases in its second quarter 2021.
PerkinElmer agrees to acquire Sirion Biotech
PerkinElmer has entered into an agreement to acquire Sirion Biotech, a provider of viral vector-based technology for cell and gene therapies. The acquisition...
PerkinElmer contributes resources to public cell painting dataset
PerkinElmer is providing its PhenoVue cell painting kits to the Joint Undertaking in Morphological Profiling-Cell Painting consortium to help speed drug...
PerkinElmer to acquire Nexcelom for $260M
PerkinElmer has entered into an agreement to acquire life sciences instrumentation firm Nexcelom Bioscience for $260 million, a deal that is expected...

Copyright © 2021 scienceboard.net


Conferences
Northeast Regional Laboratory Staff and Core Directors (NERLSCD) 2021
November 3-5
Portsmouth, New Hampshire United States
CPhI Worldwide 2021
November 9-11
Milan, Lombardia Italy
Society for Immunotherapy of Cancer (SITC) Annual Meeting
November 10-14
Washington, DC, District of Columbia United States
Connect
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter